Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00526695
Recruitment Status : Unknown
Verified July 2008 by University of Zurich.
Recruitment status was:  Recruiting
First Posted : September 10, 2007
Last Update Posted : July 18, 2008
Information provided by:
University of Zurich

Brief Summary:

Sevoflurane preconditioning and cardiovascular protection against ischemia/reperfusion injury.

Study hypothesis: The volatile anesthetic sevoflurane at subanesthetic concentrations achieves endothelial protection against ischemia/reperfusion injury and reduces inflammatory markers in the circulation

Condition or disease Intervention/treatment Phase
Ischemia/Reperfusion Injury Drug: Sevoflurane (Preconditioning) Phase 4

Detailed Description:

Healthy volunteers are included in the study to investigate endothelial function and platelet activation after preconditioning by sevoflurane in subanesthetic concentrations.

Forearm perfusion, endothelial function and leukocyte/thrombocyte activation after tourniquet-induced ischemia/reperfusion injury of the forearm are measured using healthy volunteers in a cross-over design.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers
Study Start Date : January 2005
Estimated Primary Completion Date : December 2008
Estimated Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Sevoflurane
U.S. FDA Resources

Intervention Details:
    Drug: Sevoflurane (Preconditioning)
    Inhalation of sub-anesthetic doses of sevoflurane

Primary Outcome Measures :
  1. marker expression on blood cells [ Time Frame: December 2008 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria: male

  • Non-smoker
  • No asthma
  • NPO
  • Volunteer

Exclusion criteria:

  • Female
  • Chronic medication
  • Asthma
  • Smoking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00526695

Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

University Hospital of Zurich Recruiting
Zurich, Switzerland
Contact: Michael Zaugg, MD   
Principal Investigator: Michael Zaugg, MD         
Sponsors and Collaborators
University of Zurich
Principal Investigator: Michael Zaugg, PD Dr. med. UniversitaetsSpital Zuerich
Principal Investigator: Michael Zaugg, PD Dr. med. University of Zurich

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Michael Zaugg, Anesthesiology, Univ. Hospital Zurich Identifier: NCT00526695     History of Changes
Other Study ID Numbers: 17-2005
First Posted: September 10, 2007    Key Record Dates
Last Update Posted: July 18, 2008
Last Verified: July 2008

Keywords provided by University of Zurich:
Organ Protection

Additional relevant MeSH terms:
Reperfusion Injury
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs